BRPI0406823A - Inibidores amida e éster de metaloproteinases de matriz - Google Patents

Inibidores amida e éster de metaloproteinases de matriz

Info

Publication number
BRPI0406823A
BRPI0406823A BR0406823-8A BRPI0406823A BRPI0406823A BR PI0406823 A BRPI0406823 A BR PI0406823A BR PI0406823 A BRPI0406823 A BR PI0406823A BR PI0406823 A BRPI0406823 A BR PI0406823A
Authority
BR
Brazil
Prior art keywords
inhibitors
compounds
amide
formula
matrix metalloproteinases
Prior art date
Application number
BR0406823-8A
Other languages
English (en)
Portuguese (pt)
Inventor
Amy Mae Bunker
Joseph Armand Picard
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of BRPI0406823A publication Critical patent/BRPI0406823A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C07D239/96—Two oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
BR0406823-8A 2003-01-17 2004-01-06 Inibidores amida e éster de metaloproteinases de matriz BRPI0406823A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44083703P 2003-01-17 2003-01-17
PCT/IB2004/000023 WO2004064842A1 (en) 2003-01-17 2004-01-06 Amide and ester matrix metalloproteinase inhibitors

Publications (1)

Publication Number Publication Date
BRPI0406823A true BRPI0406823A (pt) 2005-12-27

Family

ID=32771869

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0406823-8A BRPI0406823A (pt) 2003-01-17 2004-01-06 Inibidores amida e éster de metaloproteinases de matriz

Country Status (7)

Country Link
US (1) US20040142950A1 (https=)
EP (1) EP1587516A1 (https=)
JP (1) JP2006517201A (https=)
BR (1) BRPI0406823A (https=)
CA (1) CA2513115A1 (https=)
MX (1) MXPA05007607A (https=)
WO (1) WO2004064842A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6894057B2 (en) 2002-03-08 2005-05-17 Warner-Lambert Company Oxo-azabicyclic compounds
PA8578101A1 (es) * 2002-08-13 2004-05-07 Warner Lambert Co Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz
WO2005002585A1 (en) * 2003-07-02 2005-01-13 Warner-Lambert Company Llc Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor
WO2005016926A1 (en) * 2003-08-19 2005-02-24 Warner-Lambert Company Llc Pyrido [3,4-d] pyrimidine derivatives as matrix metalloproteinase-13 inhibitors
ES2524922T3 (es) 2005-05-10 2014-12-15 Intermune, Inc. Derivados de piridona para modular el sistema de proteína cinasa activada por estrés
CN101522676A (zh) * 2006-10-05 2009-09-02 Cv医药有限公司 用作硬脂酰-CoA脱氢酶抑制剂的双环含氮杂环化合物
WO2008076916A2 (en) * 2006-12-15 2008-06-26 Molecular Devices Corporation Thallium-sensitive agents and methods of using the same
US20080255161A1 (en) * 2007-04-11 2008-10-16 Dmitry Koltun 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
US20090105283A1 (en) * 2007-04-11 2009-04-23 Dmitry Koltun 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
CA2726588C (en) 2008-06-03 2019-04-16 Karl Kossen Compounds and methods for treating inflammatory and fibrotic disorders
WO2010056230A1 (en) * 2008-10-15 2010-05-20 Cv Therapeutics, Inc. 3-hydroquinazolin-4-one derivatives for use as stearoyl coa desaturase inhibitors
WO2010045374A1 (en) * 2008-10-15 2010-04-22 Gilead Palo Alto, Inc. 3-hydroquinazolin-4-one derivatives for use as stearoyl coa desaturase inhibitors
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
GB201317286D0 (en) 2013-09-30 2013-11-13 Calscience Internat Ltd Composition and Use
MX382781B (es) 2014-04-02 2025-03-13 Intermune Inc Piridinonas anti-fibroticas.
GB201410407D0 (en) * 2014-06-11 2014-07-23 Univ Dundee And Syngene Internat Ltd Plc And Consejo Superior De Investigaciones Cientificas And Med Treatment of chagas disease
RU2743074C2 (ru) 2014-08-01 2021-02-15 Нуэволюшон А/С Соединения, активные по отношению к бромодоменам
GB201502268D0 (en) 2015-02-11 2015-04-01 Calscience Internat Ltd Dental composition and use
CN109776434B (zh) * 2019-03-20 2022-01-28 中南大学 3-苄基-6-酰氨基-2,4-(1h,3h)-喹唑啉二酮衍生物及其合成方法和用途

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5385894A (en) * 1991-03-06 1995-01-31 Merck & Co., Inc. Disubstituted 6-aminoquinazolinones
US6008243A (en) * 1996-10-24 1999-12-28 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use
DE60015927T2 (de) * 1999-02-12 2005-04-07 Smithkline Beecham P.L.C., Brentford Phenylharnstoff und phenylthioharnstoffderivate
AU5826100A (en) * 1999-07-13 2001-01-30 F. Hoffmann-La Roche Ag Benzazepinones and quinazolines
PA8539301A1 (es) * 2001-02-14 2002-09-30 Warner Lambert Co Inhibidores de la metaloproteinasa de la matriz
DOP2002000333A (es) * 2001-02-14 2002-09-30 Warner Lambert Co Derivados de acido isoftalico como inhibidores de metaloproteinasas de la matriz
WO2002064571A1 (en) * 2001-02-14 2002-08-22 Warner-Lambert Company Llc Pyrimidine matrix metalloproteinase inhibitors
PA8539501A1 (es) * 2001-02-14 2002-09-30 Warner Lambert Co Compuestos triazolo como inhibidores de mmp
BR0207865A (pt) * 2001-02-14 2004-03-23 Warner Lambert Co Benzotiadiazinas inibidores de metaloproteinases de matriz
PA8539401A1 (es) * 2001-02-14 2002-10-28 Warner Lambert Co Quinazolinas como inhibidores de mmp-13
DOP2002000332A (es) * 2001-02-14 2002-08-30 Warner Lambert Co Inhibidores de piridina de metaloproteinasas de la matriz
CA2433778A1 (en) * 2001-02-14 2002-08-22 William Glen Harter Thieno'2,3-d pyrimidindione derivatives as matrix metalloproteinase inhibitors
DOP2002000334A (es) * 2001-02-14 2002-08-30 Warner Lambert Co Pirimidinas biciclicas como inhibidores de metaloproteinasas de matriz
US6924276B2 (en) * 2001-09-10 2005-08-02 Warner-Lambert Company Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors
US6962922B2 (en) * 2001-10-12 2005-11-08 Warner-Lambert Company Llc Alkynylated quinazoline compounds
BR0213233A (pt) * 2001-10-12 2005-01-04 Warner Lambert Co Alcinos inibidores de metaloproteinase de matriz
US6747147B2 (en) * 2002-03-08 2004-06-08 Warner-Lambert Company Oxo-azabicyclic compounds
US6894057B2 (en) * 2002-03-08 2005-05-17 Warner-Lambert Company Oxo-azabicyclic compounds
US20040006077A1 (en) * 2002-06-25 2004-01-08 Bernard Gaudilliere Thiazine and oxazine derivatives as MMP-13 inhibitors
AU2003250465A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc 5,6-fused uracil derivatives as matrix metalloproteinase inhibitors
JP2006500350A (ja) * 2002-08-13 2006-01-05 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー マトリックスメタロプロテイナーゼ阻害剤としてのイソキノリン誘導体
PA8578101A1 (es) * 2002-08-13 2004-05-07 Warner Lambert Co Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz
AU2003249539A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc Cyclic compounds containing zinc binding groups as matrix metalloproteinase inhibitors
WO2004014388A1 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc 6,6-fused heteroaryl derivatives as matrix metalloproteinase inhibitors
AU2003249535A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc 1,6-fused uracil derivatives as matrix metalloproteinase inhibitors
WO2004014377A1 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc 4-hydroxyquinoline derivatives as matrix metalloproteinase inhibitors
MXPA05001783A (es) * 2002-08-13 2005-04-25 Warner Lambert Co Derivados de pirimidina-2,4-diona como inhibidores de las metaloproteinasas de matriz.
WO2004014892A1 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc Monocyclic derivatives as matrix metalloproteinase inhibitors
AU2003250470A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc Pyrimidinone fused bicyclic metalloproteinase inhibitors
WO2004014389A1 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc 3,4-dihydroquinolin-2-one, 5,6-fused oxazin-3-one, and 5,6-fused thiazin-3-one derivatives as matrix metalloproteinase inhibitors
AU2003250475A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc 5,6-fused 3,4-dihydropyrimidine-2-one derivatives as matrix metalloproteinase inhibitors
WO2004014916A1 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc Pyrimidine fused bicyclic metalloproteinase inhibitors
EP1539709A1 (en) * 2002-08-13 2005-06-15 Warner-Lambert Company LLC Azaisoquinoline derivatives as matrix metalloproteinase inhibitors
AU2003250482A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc Phthalimide derivatives as matrix metalloproteinase inhibitors
WO2004014909A1 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors
WO2004014375A2 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc Fused bicyclic metalloproteinase inhibitors
WO2004014378A1 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc 3-isoquinolinone derivatives as matrix metalloproteinase inhiitors
JP2005539020A (ja) * 2002-08-13 2005-12-22 ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー マトリクスメタロプロテイナーゼ阻害物質としてのクロモン誘導体
AU2003249477A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc Heterobicylcic metalloproteinase inhibitors

Also Published As

Publication number Publication date
MXPA05007607A (es) 2005-09-30
US20040142950A1 (en) 2004-07-22
WO2004064842A1 (en) 2004-08-05
EP1587516A1 (en) 2005-10-26
CA2513115A1 (en) 2004-08-05
JP2006517201A (ja) 2006-07-20

Similar Documents

Publication Publication Date Title
BRPI0406823A (pt) Inibidores amida e éster de metaloproteinases de matriz
BRPI0715746B8 (pt) composto ou sal farmaceuticamente aceitável do mesmo e composição farmacêutica os compreendendo
PE20020953A1 (es) Benzotiadiazina como inhibidores de metaloproteinasas de matriz
BR0007759A (pt) Composto, processo para preparar o mesmo,composição farmacêutica, e, métodos para tratarcondições de doença mediadas pelametaloproteinase de matriz em um mamìfero emnecessidade deste, e para tratar um paciente quesofre de uma condição selecionada do grupo queconsiste de osteoartrite, artrite reumatóide,perda de cartilagem degenerativa edesenvolvimento de tumor
BR0213233A (pt) Alcinos inibidores de metaloproteinase de matriz
MX419368B (es) Heteroarilamidas utiles como inhibidores de kif18a
BRPI0412347A (pt) 2-aminofenil-4-fenilpiridinas como inibidores de quinase
BRPI0415613A (pt) novos compostos de diazaspiroalcanos e seu uso no tratamento de doenças mediadas por ccr8
UY27154A1 (es) Pirimidinas inhibidoras de metaloproteinasa de matriz
PA8571001A1 (es) 2-(2,6-diclorofenil)-diarilimidazoles
BRPI0408420A (pt) compostos de carbonila
BRPI0407919A (pt) pirrolopirimidinas espiro-substituìdas
BRPI0518467A2 (pt) derivado de Ácido antranÍlico, inibidor de produÇço de metaloprotease de matriz 13, e, agente terapÊutico para artrite reumatàide
BR0010555A (pt) Inibidores de neuraminidases
PE20080359A1 (es) Compuestos de benzoxazol y benzotiazol 6-0-sustituidos y metodos de inhibicion de la senalizacion de csf-1r
MX9400276A (es) Acidos hidroxamicos arilsulfonamido-sustituidos.
BRPI0512974A (pt) novos derivados de hidantoìna para o tratamento de doenças obstrutivas das vias aéreas
BR9808030A (pt) Certos derivados cìclicos de amida de acilaminoácido tio-substituìdos
BRPI0409739A (pt) composto, composição farmacêutica, uso de composto, e, método para o tratamento de uma doença ou de um distúrbio
BR0308419A (pt) Derivados de azetidina como antagonistas do receptor ccr-3
BRPI0411800A (pt) candidatos a fármacos e métodos para sua preparação
BR0200341A (pt) Bifenilsulfonamidas proveitosas como inibidores de metaloproteases da matriz
Tber et al. Selective inhibition of human cathepsin S by 2, 4, 6-trisubstituted 1, 3, 5-triazine analogs
US11168078B2 (en) Sulfoximine, sulfonimidamide, sulfondiimine and diimidosulfonamide compounds as inhibitors of indoleamine 2,3-dioxygenase
BR0309668A (pt) Imidazolinilmetil aralquilsulfonamidas

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.